Sandhu Sukhminder K, Hua Wei, MaCurdy Thomas E, Franks Riley L, Avagyan Armen, Kelman Jeffrey, Worrall Christopher M, Ball Robert, Nguyen Michael
Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Vaccine. 2017 May 19;35(22):2986-2992. doi: 10.1016/j.vaccine.2017.03.087. Epub 2017 Apr 24.
Guillain-Barré syndrome (GBS) is a serious acute demyelinating disease that causes weakness and paralysis. The Food and Drug Administration (FDA) began collaborating with the Centers for Medicare and Medicaid Services (CMS) to develop near real-time vaccine safety surveillance capabilities in 2006 and has been monitoring for the risk of GBS after influenza vaccination for every influenza season since 2008.
We present results from the 2010/11 to 2013/14 influenza seasons using the Updating Sequential Probability Ratio Test (USPRT), with an overall 1-sided α of 0.05 apportioned equally using a constant alpha-spending plan among 20 consecutive weekly tests, 5 ad hoc tests, and a 26th final end of season test. Observed signals were investigated using the self-controlled risk interval (SCRI) design.
Over 15 million people were vaccinated in each influenza season. In the 2010/11 influenza season, we observed an elevated GBS risk during the season, with an end of season SCRI analysis finding a nonsignificant increased risk (RR=1.25, 95% CI: 0.96-1.63). A sensitivity analysis applying the positive predictive value of the ICD-9 code for GBS from the 2009/10 season estimated a RR=1.98 (95% CI: 1.42-2.76). Although the 2010/11 influenza vaccine suggested an increased GBS risk, surveillance of the identical vaccine in the 2011/12 influenza season did not find an increased GBS risk after vaccination. No signal was observed in the subsequent three influenza seasons.
Conducting near real-time surveillance using USPRT has proven to be an excellent method for near real-time GBS surveillance after influenza vaccination, as demonstrated by our surveillance efforts during the 2010/11-2013/14 influenza seasons. In the 2010/2011 influenza season, in addition to the 2009 H1N1 influenza pandemic, using near real-time surveillance we were able to observe a signal early in the influenza season and the method has now become routine.
吉兰 - 巴雷综合征(GBS)是一种严重的急性脱髓鞘疾病,可导致肌无力和瘫痪。2006年,美国食品药品监督管理局(FDA)开始与医疗保险和医疗补助服务中心(CMS)合作,以开发近乎实时的疫苗安全性监测能力,并且自2008年以来,一直在监测每个流感季节接种流感疫苗后发生GBS的风险。
我们展示了2010/11至2013/14流感季节使用更新序贯概率比检验(USPRT)的结果,总体单侧α为0.05,使用恒定α消耗计划在连续20次每周测试、5次临时测试和第26次季末最终测试之间平均分配。使用自控风险区间(SCRI)设计对观察到的信号进行调查。
每个流感季节有超过1500万人接种疫苗。在2010/11流感季节,我们观察到该季节GBS风险升高,季末SCRI分析发现风险有非显著性增加(RR = 1.25,95% CI:0.96 - 1.63)。一项敏感性分析应用2009/10季节GBS的ICD - 9编码的阳性预测值,估计RR = 1.98(95% CI:1.42 - 2.76)。尽管2010/11流感疫苗提示GBS风险增加,但在2011/12流感季节对同一疫苗的监测未发现接种疫苗后GBS风险增加。在随后的三个流感季节未观察到信号。
正如我们在2010/11 - 2013/14流感季节的监测工作所表明的,使用USPRT进行近乎实时监测已被证明是流感疫苗接种后近乎实时监测GBS的一种出色方法。在2010/2011流感季节,除了2009年H1N1流感大流行外,使用近乎实时监测我们能够在流感季节早期观察到一个信号,并且该方法现已成为常规方法。